The Care Ledger

The market Maryland finalizes the first state payment limits on a drug, for Ozempic and Jardiance

Search
Tuesday, November 17, 2026Today's Paper From the publisher Free hospital price search Published bysoro
The Care Ledger

The market

Maryland finalizes the first state payment limits on a drug, for Ozempic and Jardiance

Starting in January, state and local government health plans in Maryland can cap what they pay for the two drugs, and a 2025 law lets the board extend the limits to private insurance from 2028.

A light blue Ozempic injection pen lying on a gray surface
An Ozempic injection pen. Maryland will cap government plan payments for the drug at $274 for a 30-day supply. Photo: HualinXMN, via Wikimedia Commons (CC BY-SA 4.0)

Maryland's Prescription Drug Affordability Board voted unanimously on Monday to approve final regulations that set upper payment limits on Ozempic and Jardiance, the Baltimore Sun reported1. The limits take effect January 1, 2027, and are the first of their kind in the nation, according to the Sun. Ozempic's limit is $274 for a 30-day supply, and Jardiance's is $204.

Why it matters

An upper payment limit is a ceiling on what a payer spends on a drug, rather than a price the manufacturer charges. For now, Maryland's limits apply only to state and local government health plans. A 2025 state law lets the board extend them to private insurance starting in 2028, Maryland Matters reported2, which would put a cap on what employers and commercial insurers pay.

The savings in the first stage go mainly to the plans, not to patients. Most of the participating government plans charge members a flat copay, so the limits are not expected to lower what people pay at the pharmacy counter, according to the Sun.

The limits

The Jardiance limit is $6.80 a pill, or $204 for a 30-day supply, and applies to drugs dispensed or purchased on or after January 1, 2027, according to the regulation text3. The board set a 2026 baseline of $198 for a 30-day supply and will adjust the limit each year for inflation starting in 2028.

The Ozempic limit is $274 for a 30-day supply, WMAR reported5. That matches the price Medicare negotiated for semaglutide, the active ingredient in Ozempic, which also takes effect in January 2027 and is 71% below list price, Managed Healthcare Executive reported6 in 2025. Wegovy, which contains the same ingredient, is not covered by Maryland's limit.

Eligible government plans can choose to use the limits in 2027, and those that take part must apply them from January 1, 2028, according to the Sun and the board's website4. Plans whose net spending on either drug runs above the limit receive supplemental rebates, the Sun reported.

An analysis by Steve Ports Consulting, commissioned by the advocacy group Maryland Health Care for All, estimates the government plans would save about $5.8 million a year on Ozempic and about $320,000 on Jardiance, Maryland Matters reported. If the limits reached all Maryland plans, the same analysis puts the savings at $113 million to $165 million a year for Ozempic and $9 million to $16 million for Jardiance.

The two sides

Supporters say the limits will save public money. Vincent DeMarco of Maryland Health Care for All called the vote a landmark move for state and local budgets, according to Maryland Matters. AARP Maryland said the limits could widen access to the medicines.

Drugmakers and some patient groups warned that insurers and pharmacy benefit managers (PBMs) could respond by adding more prior authorization and other restrictions, and that small pharmacies could be squeezed on reimbursement, the Sun reported. A representative of the Pharmaceutical Research and Manufacturers of America (PhRMA) said policymakers should focus on insurer and PBM practices instead. Novo Nordisk and Boehringer Ingelheim did not immediately respond to the Sun's requests for comment.

Context

The legislature created the board in 2019, and these are the first limits it has set on any drug, Maryland Matters reported. Other states have tried the same approach, and the Sun noted that litigation over a similar effort in Colorado is ongoing.

What comes next

The regulations go to the Maryland Register for final review, and if no problems arise they take effect January 1, 2027, according to Maryland Matters. Andrew York, the board's executive director, said the board can reconsider or rescind a limit if access problems appear, the Sun reported. Advocates plan to ask the legislature in 2027 to let the board set limits more easily on other drugs with Medicare-negotiated prices.

  • 01

    CMS proposes an anti-fraud rule it says would save nearly $90 billion

    The Centers for Medicare & Medicaid Services (CMS) said the rule would save nearly $90 billion over 10 years across Medicare, Medicaid, CHIP and the marketplace, in part by tightening Medicare Advantage audits of diagnoses that medical records do not support. Comments are due January 19, 2027.

    CMS

  • 02

    Medicaid's improper payment rate rose to 7.08%

    CMS estimates $46.84 billion in improper Medicaid payments in fiscal 2026, up from $37.39 billion, and a rate of 7.32% in traditional Medicare. CMS notes that improper payments are not a measure of fraud.

    CMS

  • 03

    52% of nonprofit hospitals got more in tax breaks than they gave back, Lown finds

    The Lown Institute put the net gap at $15.5 billion for fiscal 2023 across more than 3,000 hospitals. Mayo Clinic's Rochester hospital had the largest gap, about $366 million, MPR News reported; Mayo disputes the method.

    Lown Institute

  • 04

    Minnesota will not block Sutter Health's takeover of Allina Health

    Attorney General Keith Ellison agreed to 10 years of oversight, and Sutter committed $2.15 billion over five years.

    MPR News

Every figure in this story was checked against these sources on Tuesday, November 17, 2026.

  1. 01The Baltimore Sun via Yahoo News, "Maryland approves first-in-nation payment limits", November 16, 2026yahoo.com
  2. 02Maryland Matters via Yahoo News, "Officials give final approval to limit spending on Ozempic, Jardiance in state health plans", November 17, 2026yahoo.com
  3. 03Maryland Prescription Drug Affordability Board, "COMAR 14.01.07.02 Upper Payment Limit for Jardiance", 2026pdab.maryland.gov
  4. 04Maryland Prescription Drug Affordability Board, "Upper payment limits", accessed November 17, 2026pdab.maryland.gov
  5. 05WMAR 2 News, "Maryland is capping Ozempic costs for state employees, now everyone in 2028", 2026wmar2news.com
  6. 06Managed Healthcare Executive, "CMS negotiates a 70% discount for Ozempic and Wegovy", November 26, 2025managedhealthcareexecutive.com
  7. 07CMS, "CMS CRUSH proposed rule aims to reap nearly $90 billion in taxpayer savings", November 16, 2026cms.gov
  8. 08CMS, "Fiscal Year 2026 Improper Payments", November 16, 2026cms.gov
  9. 09Lown Institute, "Many nonprofit hospitals skimp on giving back to their communities", November 17, 2026lowninstitute.org
  10. 10MPR News, "Mayo Clinic lags behind other nonprofit hospitals in charity, community spending, analysis shows", November 17, 2026mprnews.org
  11. 11MPR News, "Allina, Sutter health care merger allowed with 10 years of oversight", November 16, 2026mprnews.org
  12. PhotoAn Ozempic injection pen. Maryland will cap government plan payments for the drug at $274 for a 30-day supply. Photo: HualinXMN, via Wikimedia Commons (CC BY-SA 4.0).commons.wikimedia.org
  1. The market

    Jefferson Health loses $81 million in a quarter as it presses insurers for higher rates

    Philadelphia's largest health system is using weak results to argue for higher commercial rates, six weeks before its contracts with three Blue Cross insurers expire.

    2 min read

  2. The market

    CVS says GLP-1 drugs would pay for themselves at about $350 a month

    CVS Health's own claims study finds that weight-loss and diabetes drugs cut hospital use but still raise what employers and plans spend per member, and it names the net price at which that would stop.

    3 min read

  3. The market

    Surgery Partners rejects a $28 bid, takes $25 a share from Bon Secours Mercy's HealthSpan

    The surgery center chain chose a hospital system's raised offer over a higher cash bid, reported to be UnitedHealth's, because the board judged the bigger number less likely to close.

    3 min read

  4. The market

    Biotech groups file the second lawsuit against Medicare's international drug price pilot

    BIO and two California trade groups asked a federal court on Friday to throw out the GLOBE model, which from January ties Medicare Part B rebates on certain drugs to prices in 19 other countries.

    3 min read